• 1
    Starling JH. Contribution to the physiology of lymph secretion. J Physiol (Lond) 1893; 14: 13153.
  • 2
    Witte MH, Witte CI, Dumont AE. Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology 1971; 61: 74250.
  • 3
    Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet 1962; ii: 1258.
  • 4
    Papper S, Belsky JL, Bleifer KH. Renal failure in Laennec's cirrhosis of the liver. Description of clinical and laboratory features. Ann Intern Med 1959; 51: 75973.
  • 5
    Kowalski HJ, Abelmann WH. The cardiac output in Laennec's cirrhosis. J Clin Invest 1953; 32: 102531.
  • 6
    Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 929.
  • 7
    Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites and renal sodium and water retention in cirrhosis: the ‘overflow’ theory of ascites formation. Ann NY Acad Sci 1970; 170: 2026.
  • 8
    Kostreve Castañer A, Kampine JP. Reflex effect of hepatic baroreceptos on renal and cardiac sympathetic nervous activity. Am J Physiol 1980; 238: R390R394.
  • 9
    Wood LJ, Massie D, McLean AJ, Dudley FJ. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. Hepatology 1988; 8: 8316.
  • 10
    LeVeen HH, Christoudias G, Ip M, Luft R, Falsk G, Grosberg S. Peritoneo-venous shunting for ascites. Ann Surg 1974; 180: 58090.
  • 11
    Fernández-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 130412.
  • 12
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis. a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 11517.
  • 13
    Henrikse JH, Bendtsen F, Sorensen TI, Stadeager C, Ring-Larsen H. Reduced central blood Volume in cirrhosis. Gastroenterology 1989; 97: 150613.
  • 14
    Khorthuis RJ, Kinden DA, Brimer GE, Slattery KA, Stogsdill P, Granger DN. Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 1988; 254: G339G345.
  • 15
    Maroro A, Ginès A, Saló J, et al. Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index. Hepatology 1994; 20: 83944.
  • 16
    Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 78893.
  • 17
    Guevara M, Bru C, Ginès P, et al. Increased cerebral vascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 3944.
  • 18
    Hori N, Wiest R, Groszman RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998; 28: 146773.
  • 19
    Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 165876.
  • 20
    Ginès P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 23441.
  • 21
    Ginès P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as comnpared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 82935.
  • 22
    Ginès A, Planas R, Angeli P, et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995; 22: 12431.
  • 23
    Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493502.
  • 24
    Ruiz del Arbol L, Monescillo A, Jiménez W, García-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction. Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 57986.
  • 25
    Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002110.
  • 26
    Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 16476.
  • 27
    Toledo C, Salmerón JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resodlution and survival in patients treated by cefotaxime. Hepatology 1993; 17: 2517.
  • 28
    Follo A, Llobet JM, Navasa M, et al. Renal impairment following spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495501.
  • 29
    Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis. relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 122732.
  • 30
    Sort P, Navasa M, Arroyo V, et al. Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 4039.
  • 31
    Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 3541.
  • 32
    Uriz J, Ginès P, Cárdenas A, et al. Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 438.
  • 33
    Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 8705.
  • 34
    Angeli P, Volpin R, Gerunda G, et al. Reversal of type-1 hepatorenal syndrome with the administration of midodrine and octreatide. Hepatology 1999; 29: 16907.
  • 35
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Metreau J. Noradrenalin for the treatment of type-1 hepatorenal syndrome (HRS). J Hepatol 2001; 34: 103A (Abstract).
  • 36
    Mulkay JP, Louis H, Donckter V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type-1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 159.
  • 37
    Ginès P, Ortega R, Uriz J, et al. Effect of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A Phase-II study. Hepatology 2001; 34: 186A (Abstract).
  • 38
    Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89: 76747.
  • 39
    Award SS, Sawada S, Solders OS, et al. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemofiltration system? ASAIO J 1999; 45: 479.
  • 40
    Mitzner SR, Stange J, Klammt S, Pesynski P, Smidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system fro critically ill patients with liver failure. J Am Soc Nephrol 2001; 12(Suppl. 17): S75S82.
  • 41
    Jalan R, Williams R. Improvement of cerebral perfusion after MARS therapy: further clues about the pathogenesis of hepatic encephalopathy? Liver Transplant 2001; 7: 7135.
  • 42
    Mittzer SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS. results of a prospective, randomized, controlled clinical trial. Liver Tranplant 2000; 6: 27786.
  • 43
    Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbent recirculating system in patients with acute-on-chronic liver failure. Liver Transplant 2001; 7: 10349.